Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

NCT01163643 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome

Interventions

DRUG: 0.3% BOL-303242-X ophthalmic suspension
DRUG: 2% BOL-303242-X ophthalmic suspension
DRUG: Placebo Comparator: Vehicle
DRUG: 1% BOL-303242-X ophthalmic suspension
DRUG: 2% BOL-303242-X ophthalmic suspension AM
DRUG: 2% BOL-303242-X ophthalmic suspension PM

Sponsor

Bausch & Lomb Incorporated